RadOnc-MRL-consultant at @harleystclinic @HCAhospitalsUK. AdaptiveRT. MRIguided.HDR-BT. SABR. Prostate, Gyn, H&N, Oligomets.
London, England
Joined April 2018
- Tweets199
- Following423
- Followers254
- Likes971
Pinned Tweet
🧵Glad to share our 10y results at #ASTRO23.
🔎looking for the biological benefit of ultrahypofractionation, safety and confort of the patient and cost-effectiveness of the process, this prospective study was initiated in 2010.
Elena Moreno-Olmedo retweeted
Presenting our data showing the benefits of SABR in OPD alongside systemic therapy. #ESTRO26
@GenesisCare @drjamesgood @crispinhiley @OwczarczykKasia @elenmol2 @PaulGearing1
Elena Moreno-Olmedo retweeted
Super paper by @elenmol2 et al from @ucl + @TheChristieNHS on #MRLinac guided central lung #SABR
📢Check out the amazing cine movies of adaption to target on the journal website (screenshot below)
➡️No grade ≥ 3 toxicities
➡️Median FU of 28 months, 66.7% of patients alive
➡️Median PFS = 5.8 months, OS = 20 months
🔗 advancesradonc.org/article/S…
Elena Moreno-Olmedo retweeted
STOPCAP at #ESMO26
Benefit of #radiotherapy in de novo M1 #prostatecancer on OS & PFS.
Restricted to <5 bone or low volume mets on conventional imaging.
No interaction with other patient/tumor characteristics.
Elena Moreno-Olmedo retweeted
As expected people resist letting go of dogma. Lets review the common examples people grasp at:
1. Nodal field size: cited as why GETUG01 was negative (S1/S2), then cited why RTOG 9413 was negative (L5/S1), then POP-RT positive (L4/L5), but definitive trial of RTOG 0924 (L4/L5) negative
#astro25
@NRGonc Rtog 0924 trial on 2500 patients testing whole pelvic RT.
Negative trial
-OS no difference
-PCSM no difference
-DM no difference
-BCR was not SS different with only 4% difference at 10 years.
-toxicity increased
3 cooperative group trials now negative: getug01, Rtog 9413, Rtog 0924.
Goodbye WPRT
Elena Moreno-Olmedo retweeted
#astro25
@NRGonc Rtog 0924 trial on 2500 patients testing whole pelvic RT.
Negative trial
-OS no difference
-PCSM no difference
-DM no difference
-BCR was not SS different with only 4% difference at 10 years.
-toxicity increased
3 cooperative group trials now negative: getug01, Rtog 9413, Rtog 0924.
Goodbye WPRT
Elena Moreno-Olmedo retweeted
Critically important. We have 2 RCTs addressing this question: @GiulioFrancoli1 #ARTO (MDT + abi > abi) and T Niazi #PCS IX (MDT + Enza > Enza)
Also have #EXTEND and #RADIOSA showing MDT + ADT > ADT or MDT in mHSCP.
In my mind leading question is doublet ARPI + MDT in mHSPC
Another proof that metastasis directed therapy improves outcomes, this time in castration resistant #prostatecancer
Congrats to the PCS IX team!
author link at @TheLancetOncol: authors.elsevier.com/a/1liJQ…
Elena Moreno-Olmedo retweeted
Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial
sciencedirect.com/science/ar…
The phase 2 EXTEND trial showed that in patients with oligometastatic #ProstateCancer adding metastasis-directed therapy (MDT) to androgen deprivation therapy (ADT)💊 significantly improved progression-free survival compared with ADT alone (36 vs 17 months in combined analysis), with consistent benefits in radiologic and castration resistance–free survival; translational analyses revealed that MDT + ADT enhanced systemic immune activation, particularly T-cell receptor dynamics, suggesting both a durable clinical benefit and potential synergy with future immunotherapy strategies.
@AlexSherryMD
@BSiddiquiMD
@cara_haymaker
@ASeoMDPhD
@kieko_hara
@StephenChunMD
@ChapinMD
@matthewdeek
@woodlandscancer
@aaparicioMD
@DrLCohen
@AReubenPhD
@sumit_subudhi
@ChadTangMD
@silkegillessen @AOmlin
@nataliagandur @bavilima @yekeduz_emre
Elena Moreno-Olmedo retweeted
High-risk prostate cancer patients had a significantly lower incidence of distant metastasis with a radiotherapy-based treatment strategy than with a prostatectomy-based treatment #radonc #pcsm
sciencedirect.com/science/ar…
MR- vs CT-guided: nearly half GU toxicity!!💥💥💥
📢 New in European Urology @AmarUKishan et al:
🎯 MRI-guided SBRT for prostate cancer significantly reduces late GU and GI toxicity vs CT-guided SBRT at 2 years!
🔬 In the MIRAGE RCT, MRI guidance with tighter margins (2 mm) halved GU toxicity (27% vs 51%) and markedly reduced GI toxicity (1.4% vs 9.5%).
💡 Also linked to better bowel & sexual function scores. Proof-of-principle for aggressive margin reduction using advanced imaging.
📄 Read more: buff.ly/bIJ3ocU
#ProstateCancer #Radiotherapy #MRI #SBRT #UroRadOnc #EurUrol
Elena Moreno-Olmedo retweeted
📢 New in European Urology @AmarUKishan et al:
🎯 MRI-guided SBRT for prostate cancer significantly reduces late GU and GI toxicity vs CT-guided SBRT at 2 years!
🔬 In the MIRAGE RCT, MRI guidance with tighter margins (2 mm) halved GU toxicity (27% vs 51%) and markedly reduced GI toxicity (1.4% vs 9.5%).
💡 Also linked to better bowel & sexual function scores. Proof-of-principle for aggressive margin reduction using advanced imaging.
📄 Read more: buff.ly/bIJ3ocU
#ProstateCancer #Radiotherapy #MRI #SBRT #UroRadOnc #EurUrol
Elena Moreno-Olmedo retweeted
📢The experience from @RadioterapiaHM is just out!!
🎯Clinician- And Patient-Reported Outcomes Of Stereotactic Ablative Radiotherapy For High-Risk Prostate Cancer
#radonc #pcsm #SABR
practicalradonc.org/article/…
Elena Moreno-Olmedo retweeted
🧾 New Cheat Sheet on Prostate Cancer Treatment by Stage
🔹 Low-risk: Active surveillance; avoid ADT
🔹 Intermediate-risk: Surgery or RT; ADT case-based
🔹 High-risk: Surgery/RT + long-term ADT
#EAUguidelines #ProstateCancer
Download Cheat Sheet here:
uroweb.org/guidelines/prosta…
Elena Moreno-Olmedo retweeted
📢This might just be THE DEFINITIVE meta-analysis of PSMA PET for #prostatecancer recurrence.
🚨Meta-analysis of 43 studies (n=8,119)
⬆️Sensitivity from 48% at PSA 0.2–0.5 ng/ml to >90% at PSA >2. Congrats @declangmurphy @drMPerera + team @Uroweb!
➡️link shorturl.at/unfn5
Elena Moreno-Olmedo retweeted
Proud to see EMERALD Trial findings presented at #ESTRO2025 by Dr. Somnath Mukherjee! Watch this short video from @drjamesgood to discover how MR-guided SABR is transforming pancreatic cancer treatment 🎥
Click to download ESTRO presentation 👉🏽 bit.ly/4d4MHbC
That’s a wrap #ESTRO25! @ESTRO_RT Proud to see the hard work&commitement of the @GenesisCare to providing experience-based evidence in the pursuit of clinical improvement! Here our contribution to #SMART using MRIdian on #upperGI linkedin.com/posts/elena-mor…
Elena Moreno-Olmedo retweeted
SBRT + 💊 in oligomets:
🧍♂️2294 pts | 🫁, breast, prostate, colorectal
⚠️Grade 3+ AEs: 1.5%
✅ SBRT Safe with systemic tx!
#SBRT #OligoCare #ESTRO25 @EORTC @ESTRO_RT @CiroFranzese1
💎 EMERALD trial in #ESTRO25
Congratulations Dr. Mukherjee for excellent presentation! Honored to have worked w/you.
🎯 3-arm safety trial investigating #SMART in localised #PancreaticCancer (50 Gy/5, 39 Gy/3, 25 Gy/1)
👏🏽Big shout-out to all authors
@GenesisCare @UniofOxford
Massive thanks for the support and collaboration to @GenesisCare UK , @UniofOxford and @NHSEngland (OUH)
Elena Moreno-Olmedo retweeted
🚨10y results of HYPO RT PC at #ESTRO25
Hypofractionated #prostatecancer RT (42,7/7) vs conv fractionated RT
1. Non inferior for FFS (even better?)
2. Similar bPFS, DMFS, ADT use, OS
3. Similar GU/GI tox (except transient flare at 1y for UHF)
